Marvin & Palmer Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$4.9M |
| 2 |
Eli Lilly
LLY
|
+$4.86M |
| 3 |
Walt Disney
DIS
|
+$4.84M |
| 4 |
Pfizer
PFE
|
+$4.82M |
| 5 |
Ecolab
ECL
|
+$4.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P Small-Cap ETF
IJR
|
+$8.77M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$7.16M |
| 3 |
State Street SPDR S&P Retail ETF
XRT
|
+$6.07M |
| 4 |
SCHW
Charles Schwab
SCHW
|
+$5.17M |
| 5 |
Amphenol
APH
|
+$4.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 31.23% |
| 2 | Healthcare | 21.71% |
| 3 | Technology | 15.94% |
| 4 | Consumer Discretionary | 6.48% |
| 5 | Communication Services | 4.02% |
Similar funds
Marvin & Palmer Associates's Q4 2018 Portfolio in Review
As of Q4 2018, Marvin & Palmer Associates held 36 positions worth $116M, down 12% from $132M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Marvin & Palmer Associates withdrew a net $5.49M in Q4 2018, closing 9 positions and reducing 3 holdings. Its most notable exit was iShares Core S&P Small-Cap ETF, an estimated $8.77M position sold in full.
By sector, the portfolio is most concentrated in Financials at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Marvin & Palmer Associates opened a new position in Merck worth $5.06M.
- Marvin & Palmer Associates's largest Q4 2018 buy was Merck: 69,411 shares worth $5.06M.
- Marvin & Palmer Associates added most to Thermo Fisher Scientific in Q4 2018, an estimated $1.19M increase.
- Marvin & Palmer Associates's biggest Q4 2018 reduction was Apple, cutting an estimated $1.98M.
- Marvin & Palmer Associates fully exited iShares Core S&P Small-Cap ETF in Q4 2018, selling an estimated $8.77M.
- Marvin & Palmer Associates's ten largest holdings make up 52% of its $116M portfolio in Q4 2018.
- Marvin & Palmer Associates opened 10 new positions and closed 9 in Q4 2018.
- Marvin & Palmer Associates's portfolio value fell 12% quarter-over-quarter to $116M.
Based on Marvin & Palmer Associates's 13F filing for Q4 2018, filed 12 Feb 2019.